Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model

Bibliographic Details
Main Authors:	Despiegel Nicolas, Kuehne Felicitas, Martin Monique, Shelbaya Ahmed
Format:	Article
Language:	English
Published:	BMC 2012-05-01
Series:	Retrovirology

Similar Items

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
by: Gilles Pialoux, et al.
Published: (2015-01-01)

Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)

Optimizing management of treatment-na&iuml;ve and treatment-experienced HIV+ patients: the role of maraviroc
by: Eva Poveda, et al.
Published: (2010-03-01)

Effectiveness and cost of treatment with maraviroc in HIV infection
by: Viola Sacchi, et al.
Published: (2009-01-01)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015-10-01)

Etnografía de un caso de «alta tecnología»: sobre Aramis
by: Bruno Latour
Published: (1993-01-01)

Using ARAMIS system for measurement of structural stability of running wind tunnel
by: Yanovych Viatlii, et al.
Published: (2020-01-01)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016-01-01)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
by: Schols Dominique, et al.
Published: (2011-10-01)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
by: Poizot-Martin Isabelle, et al.
Published: (2010-05-01)

Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
by: Marilyn Lewis, et al.
Published: (2018-01-01)

Research of Load and Contact Capacity of Micro-Segment Gear based on ARAMIS System
by: Huang Kang, et al.
Published: (2015-01-01)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
by: Christophe Rodriguez, et al.
Published: (2015-01-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)

Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.
by: Borislav Savkovic, et al.
Published: (2012-01-01)

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
by: Ai Kawana-Tachikawa, et al.
Published: (2014-01-01)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
by: Jintanat Ananworanich, et al.
Published: (2015-04-01)

Iki Dil, İki Halk, Tek Cografya: Luvi-Arami İlişkileri (MO 1050-750)
by: Kürşat Bardakcı
Published: (2020-04-01)

Lack of effect of Maraviroc intensification on blood and gut reservoir.
by: Tiraboschi, J, et al.
Published: (2016)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
by: Sambit Tripathy
Published: (2021-01-01)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
by: María Rosa López-Huertas, et al.
Published: (2020-12-01)

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.
by: Saleta Sierra, et al.
Published: (2015-01-01)

Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model.
by: Laura Ochoa-Callejero, et al.
Published: (2013-01-01)

Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
by: C Preston Neff, et al.
Published: (2010-12-01)

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
by: Valérie Potard, et al.
Published: (2015-01-01)

The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV
by: Hitchcock CA
Published: (2005-12-01)

Examples of the Use of the ARAMIS 3D Measurement System for the Susceptibility to Deformation Tests for the Selected Mixtures of Coal Mining Wastes
by: Konrad Walotek, et al.
Published: (2021-07-01)

Harmonised Approach to the Assessment of Major Accident Risks in the Framework of Seveso II Directive: Case Study on Aramis Methodology Application
by: Ales Bernatik, et al.
Published: (2005-09-01)

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
by: Nicholas Funderburg, et al.
Published: (2010-10-01)

Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients.
by: Silvia Nozza, et al.
Published: (2012-01-01)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
by: María Rosa López-Huertas, et al.
Published: (2017-05-01)

30LB Maraviroc administration is associated to reversion of latent HIV-1 through NFkB in ART suppressed patients
by: N. Madrid-Elena, et al.
Published: (2016-07-01)

Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone
by: Robert G. Micheletti, et al.
Published: (2020-04-01)

Ação do governo militar na cultura e a crítica de música popular brasileira de Aramis Millarch
by: Rogério de Brito Bergold, et al.
Published: (2018-04-01)

Fármacos recentes usados para o tratamento da infecção pelo HIV-1: enfuvirtida, maraviroc, raltegravir e etravirina
by: M.A. Brito
Published: (2011-05-01)

Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
by: S. Moreno, et al.
Published: (2019-12-01)

No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV infected patients receiving suppressive maraviroc therapy
by: J. Izopet, et al.
Published: (2015-12-01)

Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome.
by: Laura Pérez-Martínez, et al.
Published: (2024-01-01)